Mineralys Therapeutics says Phase 2 Explore-CKD trial of lorundrostat met primary endpoint, results published in Kidney International

Mineralys Therapeutics announced its Phase 2 Explore-CKD trial of the aldosterone synthase inhibitor lorundrostat met its primary endpoint: a 25 mg once-daily dose added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks. Full results were published in the journal Kidney International.

Detected & updated continuously · Source: Nebula